share_log

Aethlon Medical | 10-Q: Q1 2025 Earnings Report

Aethlon Medical | 10-Q: Q1 2025 Earnings Report

Aethlon Medical | 10-Q：2025财年一季报
美股SEC公告 ·  08/15 06:15

Moomoo AI 已提取核心信息

Aethlon Medical reported financial results for Q1 FY2025 ended June 30, 2024. Net loss decreased to $2.57M from $3.28M in Q1 FY2024, with operating expenses down 23.1% to $2.62M. Cash balance increased to $9.07M from $5.44M at March 31, 2024.The company made progress on its oncology clinical trials, receiving ethics approvals for studies in Australia. It raised $5.38M through a public offering and warrant exercises. Aethlon is advancing trials of its Hemopurifier device for cancer and viral diseases, with studies planned or underway in Australia, India, and the U.S.Management expects existing cash to fund operations for at least 12 months. The company alleviated previous going concern doubts through fundraising and reduced expenses. Aethlon continues to work on qualifying a new supplier for a key Hemopurifier component and manufacturing devices at its San Diego facility for planned U.S. trials.
Aethlon Medical reported financial results for Q1 FY2025 ended June 30, 2024. Net loss decreased to $2.57M from $3.28M in Q1 FY2024, with operating expenses down 23.1% to $2.62M. Cash balance increased to $9.07M from $5.44M at March 31, 2024.The company made progress on its oncology clinical trials, receiving ethics approvals for studies in Australia. It raised $5.38M through a public offering and warrant exercises. Aethlon is advancing trials of its Hemopurifier device for cancer and viral diseases, with studies planned or underway in Australia, India, and the U.S.Management expects existing cash to fund operations for at least 12 months. The company alleviated previous going concern doubts through fundraising and reduced expenses. Aethlon continues to work on qualifying a new supplier for a key Hemopurifier component and manufacturing devices at its San Diego facility for planned U.S. trials.
Aethlon Medical公布了截至2024年6月30日的2025财年第一季度财务结果。净亏损从2024财年第一季度的328万美元减少至257万美元，营业费用下降了23.1%，至262万美元。现金余额从2024年3月31日的544万美元增加到907万美元。公司在其肿瘤学临床试验方面取得了进展，获得了在澳洲进行研究的伦理批准。通过公开募股和认股权证行使筹集了538万美元。Aethlon正在推进其针对癌症和病毒疾病的Hemopurifier设备的试验，并计划或正在澳洲、印度和美国进行相关研究。管理层预计现有现金能够支持运营至少12个月。公司通过筹款和减少支出消除了之前的持续经营疑虑。Aethlon继续致力于为关键的Hemopurifier组件认证新的供应商，并在其位于圣迭戈的设施中制造设备，以便为计划中的美国试验做准备。
Aethlon Medical公布了截至2024年6月30日的2025财年第一季度财务结果。净亏损从2024财年第一季度的328万美元减少至257万美元，营业费用下降了23.1%，至262万美元。现金余额从2024年3月31日的544万美元增加到907万美元。公司在其肿瘤学临床试验方面取得了进展，获得了在澳洲进行研究的伦理批准。通过公开募股和认股权证行使筹集了538万美元。Aethlon正在推进其针对癌症和病毒疾病的Hemopurifier设备的试验，并计划或正在澳洲、印度和美国进行相关研究。管理层预计现有现金能够支持运营至少12个月。公司通过筹款和减少支出消除了之前的持续经营疑虑。Aethlon继续致力于为关键的Hemopurifier组件认证新的供应商，并在其位于圣迭戈的设施中制造设备，以便为计划中的美国试验做准备。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间